NBTX · Nanobiotix

The thesis

Nanobiotix shares are more likely to lag the S&P 500 over the next three months than to lead it. The trial that decides the company's value, the Phase 3 NANORAY-312 study of JNJ-1900 (NBTXR3) in head and neck cancer, has no announced readout date. The two November investor conferences and any word on NANORAY-312 timing are what could change that.

The balance sheet is not the problem. Cash stood at €110.9 million on 30 June 2026, and the company's first-half update of 24 September 2026 says that funds operations into 2029. The problem is time. A protocol amendment dropped the planned interim analysis in favour of a final analysis on fewer events. The company says the final analysis should come in a similar timeframe to the old interim, but that timing depends on when the event count is reached. Without a dated readout, the shares have no scheduled catalyst inside the next 63 trading sessions.

What the price already reflects: the shares closed at $32.95 on 11 November 2026. That is below the $38.98 per American Depositary Share (ADS) price of the global offering that closed on 26 May 2026 and 42.3% below the intraday 52-week high of $57.14 on 14 May 2026. The market has taken back most of the spring run while it waits for the Phase 3 result.

Bullish and bearish views on Nanobiotix S.A.

The bull case on Nanobiotix S.A. (NBTX), in brief: cash runs into 2029. The bear case: no dated readout for NANORAY-312.

Bull case

• Cash runs into 2029. Cash was €110.9 million on 30 June 2026, up from €52.8 million on 31 December 2025, after the global offering of about $100 million gross that closed on 26 May 2026 (company releases of 26 May 2026 and 24 September 2026).
• Partner funds the pivotal trial. Johnson & Johnson's Janssen unit runs NANORAY-312 under a 2023 licence, and Nanobiotix's first-half 2026 research and development spending fell to €12.7 million from €14.5 million a year earlier (first-half update, 24 September 2026).
• Melanoma data added a second indication. Final Phase 1 data from Study 1100, presented at the European Society for Medical Oncology (ESMO) congress on 24 October 2026, showed a 41.7% response rate, 4 complete responses, a 75% disease control rate and 17.8-month median overall survival in anti-PD-1-resistant melanoma (company release, 24 October 2026).
• A faster path to the final analysis. The NANORAY-312 amendment removed the interim analysis and cut the number of events needed for the final analysis, so the final read should come sooner than under the original design (first-half update, 24 September 2026).

Bear case

• No dated readout for NANORAY-312. The 24 September 2026 update gives no year or half for the final analysis and ties it to an event count that Janssen's trial must reach.
• Shares trade below the offering price. The 11 November 2026 close of $32.95 sits under the $38.98 per-ADS price that institutions paid in May 2026, a price already set at a 14.92% discount to the prior three-session average (closing release, 26 May 2026).
• Losses widened sharply. The first-half 2026 net loss was €34.3 million against €5.4 million a year earlier, and revenue and other income fell to €5.6 million from €26.6 million, which had included a one-off €21.2 million non-cash item (first-half update, 24 September 2026).
• Melanoma data is early. The ESMO results come from a single-arm Phase 1 study; they do not substitute for a randomised Phase 3 outcome.
• Finance leadership changed. Arnd Christ became chief financial officer on 1 October 2026, succeeding Bart Van Rhijn after five years (company 6-K, 1 October 2026).

Price setup

Adjusted daily closes put the shares at $32.95 on 11 November 2026. That is above the 50-day moving average of $30.71 and below the 200-day moving average of $34.22, both as of the same close. The 3-month change is −13.7%, measured against the $38.17 close of 13 August 2026.

The shares recovered from $29.70 on 4 November 2026 to $32.95 on 11 November 2026, closing higher in each of the last five sessions. The 200-day average at $34.22 is the first level above the price. The $38.17 close of 13 August 2026 and the $38.98 per-ADS offering price of May 2026 sit above that. The 52-week closing low is $19.97 on 8 January 2026; the 52-week intraday high is $57.14 on 14 May 2026.

Catalysts ahead

• 16 November 2026: Chief executive Laurent Levy and finance chief Arnd Christ present at the Jefferies Global Healthcare Conference, London. The first management appearance since the ESMO melanoma data; any update on NANORAY-312 event accrual or final-analysis timing would bear directly on the call.
• 17 November 2026: Management participates in the UBS Global Biopharma Conference, London. A second venue for guidance on the Phase 3 readout window and on plans for the melanoma indication.
• ~31 March 2027 (est.): Full-year 2026 results and 20-F filing. Shows second-half 2026 cash burn against the runway into 2029 and may give the first dated window for the NANORAY-312 final analysis.

What would change the view

A daily close above $38.17, the 13 August 2026 close, which would erase the three-month decline and show the shares leading; or an announcement that the NANORAY-312 final analysis met its primary endpoint.

What it trades with

Nanobiotix trades mainly on its own clinical and partner news. Its main asset is licensed to Johnson & Johnson, so a statement from Janssen about NANORAY-312 matters more to the shares than sector moves. The ordinary shares also trade on Euronext Paris (ticker NANO), so Paris trading and the euro-dollar exchange rate feed into the US-listed ADS. Other Oncology & immunology names (Xencor, Genmab, Replimune) report on their own trial schedules; none shares a readout with Nanobiotix.